Skip to main content
Fig. 1 | Clinical Epigenetics

Fig. 1

From: PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy

Fig. 1

Genomic location, design, and validation of the PITX3 QM Assay. a PITX3 quantitative-methylation (QM) assay located on the reverse strand of chromosome 10. Both PITX3 splice variants PITX3-001 and PITX3-201 are shown. The information was taken from Ensembl Homo sapiens version 82.38 (GRCh38.p3). The two beads of the Illumina Infinium HumanMethylation450 BeadChip (cg12324970 and cg23095743) used from the TCGA dataset are shown. The GC content (%) is shown with the dashed line indicating 50 % GC. b The QM real-time PCR assay was validated on a dilution series of bisulfite-converted artificially methylated and unmethylated DNA. Each sample was measured in duplicate

Back to article page